BENGALURU: Indian biopharmaceutical company Biocon says it would fully integrate its biosimilar unit Biocon Biologics as a wholly owned subsidiary, consolidating Biocon’s biosimilars and generics businesses under one roof.
Biocon said it will acquire the remaining stakes in Biocon Biologics from Serum Institute Life Sciences, Tata Capital Growth Fund II and Activ Pine LLP through a share swap of 70.28 Biocon shares for every 100 Biocon Biologics shares, at a price of 405.78 rupees (US$4.51) per Biocon share.
